Abstract
Human immunodeficiency virus-1 (HIV-1) has a high degree of genetic and antigenic diversity that has impeded the development of an effective vaccine using traditional methods. We are attempting to develop an AIDS vaccine by employing strategies that include structural biology and computational modelling, in an effort to develop immunogens capable of eliciting neutralizing antibodies of the requisite breadth and potency against circulating strains of HIV-1.
MeSH terms
-
AIDS Vaccines / immunology*
-
Antibodies, Neutralizing / immunology
-
Antibody Formation
-
Binding Sites, Antibody
-
CD4 Antigens / immunology
-
Computational Biology*
-
Drug Design*
-
HIV Envelope Protein gp120 / chemistry
-
HIV Envelope Protein gp120 / immunology
-
HIV Envelope Protein gp41 / immunology
-
HIV Infections / immunology
-
HIV Infections / prevention & control*
-
HIV Infections / virology
-
HIV-1 / immunology
-
HIV-1 / pathogenicity
-
Humans
Substances
-
AIDS Vaccines
-
Antibodies, Neutralizing
-
CD4 Antigens
-
HIV Envelope Protein gp120
-
HIV Envelope Protein gp41